Spots Global Cancer Trial Database for Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
Official Title: Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders
Study ID: NCT00636909
Study Description
Brief Summary: The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects. We hope to decrease these side effects by decreasing the chemotherapy dose prior to transplant (non-myeloablative, smaller dose of chemotherapy given so bone marrow is not completely eliminated) and by using donated stem cells to treat cancer of the blood.
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: David F McDermott, MD
Affiliation: Beth Israel Deaconess Medical Center
Role: PRINCIPAL_INVESTIGATOR
Name: David E Avigan, MD
Affiliation: Beth Israel Deaconess Medical Center
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
